NEW YORK – Sophia Genetics on Monday said it has entered into a research partnership with the Spanish Lung Cancer Group to identify biomarkers of response to neoadjuvant nivolumab (Bristol Myers Squibb's Opdivo) plus chemo in non-small cell lung cancer patients.
Specifically, the Swiss-American bioinformatics company and the non-profit, cooperative group of Spanish medical professionals will team up to apply a multi-modal machine-learning model that can retrospectively predict responses in stage IIIA NSCLC patients who received neoadjuvant nivolumab plus platinum-based chemotherapy in the Phase II NADIM trial. The predictive model will combine patients' radiology images from Sophia's radiomics platform with clinical, biologic, and genomics data from the trial.
Sophia will use the predictive model to stratify patients bases on their progression-free survival and overall survival to neoadjuvant treatment. The NADIM trial involves 18 centers within the Spanish Lung Cancer Group, all of whom have agreed to share patient data with Sophia for the project.
"Unlocking the synergistic potential of multimodal health data through artificial intelligence holds revolutionary promise for the future of personalized medicine in oncology and many other health conditions," Philippe Menu, Sophia's chief medical officer, said in a statement. "We are inspired by the potential to positively impact patients by supporting their care providers in predicting the best course of treatment."
The results of the NADIM trial, which supported the addition of nivolumab to adjuvant chemo, were published in the Lancet Oncology in September 2020, and Sophia and the Spanish Lung Cancer Group expect to make the results of this additional analysis available later in 2021.